NasdaqGS:NVAXBiotechs
Novavax (NVAX) Stock Revalued After Pivot To Sanofi Deal And Matrix M Licensing Model
Novavax (NVAX) is reshaping its business model after handing European commercialization of its COVID-19 vaccine to Sanofi and prioritizing partnerships that license out its Matrix-M adjuvant technology.
See our latest analysis for Novavax.
Recent stock moves reflect that shift in focus. Despite a 1-day share price return of 5.49% to US$9.03, the 7-day and 90-day share price returns are down 11.38% and 11.77%. The year-to-date share price return of 26.65% sits alongside a 1-year total...